- RecruitingPHASE3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
This study compares a new medicine, deucravacitinib, with an existing one, ustekinumab, for long-term safety in people with moderate to severe plaque psoriasis. It focuses on participants who also have heart disease risk factors.
For: Plaque PsoriasisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. It compares the new medication to a widely used treatment (ustekinumab) and a dummy medicine (placebo) to see how safe and effective it is.
For: Plaque PsoriasisUnited States · Argentina · Australia - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
For: Crohn's Disease (CD)United States · Argentina · Australia - Active not recruitingPHASE3
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
This study is looking into two medicines, ustekinumab and guselkumab, for children and young people aged 5-17 with juvenile psoriatic arthritis. We want to see how well these medicines work, if they are safe, and how the body handles them to help manage this type of arthritis.
For: Arthritis, JuvenileUnited States · Argentina · Denmark - RecruitingPHASE4
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
This study looks at new ways to treat Crohn's disease. Researchers are testing if combining two medicines, vedolizumab and either adalimumab or ustekinumab, works better than vedolizumab alone for adults with moderate to severe Crohn's.
For: Crohn's DiseaseUnited States · Canada - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
For: Crohn's DiseaseUnited States · Australia · Austria - Active not recruiting
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
This study looks at the long-term safety of ustekinumab in children and teenagers (6-17) with moderate to severe plaque psoriasis. Researchers will monitor for serious infections, cancers, and autoimmune issues, as well as checking the drug's effects on growth and development.
For: PsoriasisAustria · Belgium · Denmark - Active not recruitingPHASE3
A Long-term Extension Study of Ustekinumab in Pediatric Participants
This study looks at the long-term safety of a treatment called ustekinumab for children and young people with conditions like Crohn's disease or certain types of arthritis. It's for those already taking part in an earlier study of this medicine.
For: Crohn Disease · Colitis, Ulcerative · Arthritis, PsoriaticUnited States · Argentina · Belgium